These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36130185)

  • 1. The role of microRNAs in the pathophysiology, diagnosis, and treatment of diabetic cardiomyopathy.
    Abdel Rhman M; Owira P
    J Pharm Pharmacol; 2022 Nov; 74(12):1663-1676. PubMed ID: 36130185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics.
    Jakubik D; Fitas A; Eyileten C; Jarosz-Popek J; Nowak A; Czajka P; Wicik Z; Sourij H; Siller-Matula JM; De Rosa S; Postula M
    Cardiovasc Diabetol; 2021 Feb; 20(1):55. PubMed ID: 33639953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy.
    Mathur P; Rani V
    Curr Gene Ther; 2021; 21(4):313-326. PubMed ID: 33719971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological Functions and Clinical Prospects of Extracellular Non-Coding RNAs in Diabetic Cardiomyopathy: an Updated Review.
    Yin Z; Chen C
    J Cardiovasc Transl Res; 2022 Jun; 15(3):469-476. PubMed ID: 35175553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides.
    Ghosh N; Katare R
    Cardiovasc Diabetol; 2018 Mar; 17(1):43. PubMed ID: 29566757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and strategies of long noncoding RNA research for diabetic cardiomyopathy.
    Pant T; Dhanasekaran A; Fang J; Bai X; Bosnjak ZJ; Liang M; Ge ZD
    BMC Cardiovasc Disord; 2018 Oct; 18(1):197. PubMed ID: 30342478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in microRNA Expression Profiles in Diabetic Cardiomyopathy Rats Following H3 Relaxin Treatment.
    Zhang X; Liu M; Yang K; Chi J; Chen W; Shi Z; Liu W; Ma X; Yin X
    J Cardiovasc Pharmacol; 2022 Apr; 79(4):530-538. PubMed ID: 34983906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression profiles and bioinformatic analysis of microRNAs in myocardium of diabetic cardiomyopathy mice.
    Wang T; Yuan L; Chen Y; Wang J; Li N; Zhou H
    Genes Genomics; 2023 Aug; 45(8):1003-1011. PubMed ID: 37253907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of hub genes and potential ceRNA networks of diabetic cardiomyopathy.
    Hou J; Liang WY; Xiong S; Long P; Yue T; Wen X; Wang T; Deng H
    Sci Rep; 2023 Jun; 13(1):10258. PubMed ID: 37355664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Non-coding RNA in Diabetic Cardiomyopathy.
    Xia L; Song M
    Adv Exp Med Biol; 2020; 1229():181-195. PubMed ID: 32285412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomal microRNAs: potential targets for the prevention and treatment of diabetic cardiomyopathy.
    Zhang T; Gao Z; Chen K
    J Cardiol; 2022 Nov; 80(5):423-431. PubMed ID: 35000826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression profiling of circular RNAs and their potential role in early‑stage diabetic cardiomyopathy.
    Dong S; Tu C; Ye X; Li L; Zhang M; Xue A; Chen S; Zhao Z; Cong B; Lin J; Shen Y
    Mol Med Rep; 2020 Sep; 22(3):1958-1968. PubMed ID: 32705182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting miRNA for Therapy of Juvenile and Adult Diabetic Cardiomyopathy.
    Nandi SS; Mishra PK
    Adv Exp Med Biol; 2018; 1056():47-59. PubMed ID: 29754174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-340-5p Mediates Cardiomyocyte Oxidative Stress in Diabetes-Induced Cardiac Dysfunction by Targeting Mcl-1.
    Zhu Y; Yang X; Zhou J; Chen L; Zuo P; Chen L; Jiang L; Li T; Wang D; Xu Y; Li Q; Yan Y
    Oxid Med Cell Longev; 2022; 2022():3182931. PubMed ID: 35126811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and analysis of a lncRNA‑miRNA‑mRNA network based on competitive endogenous RNA reveals functional lncRNAs in diabetic cardiomyopathy.
    Chen K; Ma Y; Wu S; Zhuang Y; Liu X; Lv L; Zhang G
    Mol Med Rep; 2019 Aug; 20(2):1393-1403. PubMed ID: 31173240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long Noncoding RNA OIP5-AS1 Overexpression Promotes Viability and Inhibits High Glucose-Induced Oxidative Stress of Cardiomyocytes by Targeting MicroRNA-34a/SIRT1 Axis in Diabetic Cardiomyopathy.
    Sun H; Wang C; Zhou Y; Cheng X
    Endocr Metab Immune Disord Drug Targets; 2021; 21(11):2017-2027. PubMed ID: 33380310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging Actors in Diabetic Cardiomyopathy: Heartbreaker Biomarkers or Therapeutic Targets?
    Palomer X; Pizarro-Delgado J; Vázquez-Carrera M
    Trends Pharmacol Sci; 2018 May; 39(5):452-467. PubMed ID: 29605388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulation of circulating miRNAs promotes the pathogenesis of diabetes-induced cardiomyopathy.
    Ahmed U; Ashfaq UA; Qasim M; Ahmad I; Ahmad HU; Tariq M; Masoud MS; Khaliq S
    PLoS One; 2021; 16(4):e0250773. PubMed ID: 33909697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of Diabetic Cardiomyopathy and Role of miRNA.
    Ahmed U; Khaliq S; Ahmad HU; Ahmad I; Ashfaq UA; Qasim M; Masoud MS
    Crit Rev Eukaryot Gene Expr; 2021; 31(1):79-92. PubMed ID: 33639058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic overexpression of miR-92a-2-5p ameliorated cardiomyocyte oxidative stress injury in the development of diabetic cardiomyopathy.
    Yu M; Sun Y; Shan X; Yang F; Chu G; Chen Q; Han L; Guo Z; Wang G
    Cell Mol Biol Lett; 2022 Oct; 27(1):85. PubMed ID: 36209049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.